-
Abstract: Mantle cell lymphoma (MCL) accounts for about 6% of all non-Hodgkin lymphomas,and it is hard to be treated.Lenalidomide,a novel immunomodulatory agent,is a kind of thalidomide derivative.Many clinical studies have shown that lenalidomide has a good efficacy for many kinds of blood and lymphatic system diseases,and it has minor adverse events.This paper expounds the clinical research and application of lenalidomide in mantle cell lymphoma.
-
Key words:
- lenalidomide /
- mantle cell lymphoma /
- adverse event
-
-
[1] Campo E, Rule S.Mantle cell lymphoma:evolving management strategies[J].Blood, 2015, 125:48-55.
[2] Cortelazzo S, Ponzoni M, Ferreri AJ, et al.Mantle cell lymphoma[J].Crit Rev Oncol Hematol, 2012, 82:78-101.
[3] Dreyling M, Geisler C, Hermine O, et al.Newly diagnosed and relapsed mantle cell lymphoma:ESMOClinical Practice Guidelines for diagnosis, treatment and follow-up[J].Ann Oncol, 2014, 25:iii83-92.
[4] 谢彦, 朱军.套细胞淋巴瘤诊断与治疗中国专家共识 (2016版) 解读[J].临床血液学杂志, 2017, 30 (9):683-686.
[5] Williams ME, Dreyling M, Winter J, et al.Management of mantle cell lymphoma:key challenges and next steps[J].Clin Lymphoma Myeloma Leuk, 2010, 10:336-346.
[6] Dreyling M, Thieblemont C, Gallamini A, et al.ESMOConsensus conferences:guidelines on malignant lymphoma.Part 2:marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma[J].Ann Oncol, 2013, 24:857-877.
[7] Eve HE, Carey S, Richardson SJ, et al.Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma:results from a UK phase II study suggest activity and possible gender differences[J].Br J Haematol, 2012, 159:154-163.
[8] Goy A, Sinha R, Williams ME, et al.Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib:phase II MCL-001 (EMERGE) study[J].JClin Oncol, 2013, 31:3688-3695.
[9] Trněny M, Lamy T, Walewski J, et al.Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002;SPRINT):aphase2, randomised, multicentre trial[J].Lancet Oncol, 2016, 17:319-331.
[10] Dawar R, Hernandez-Ilizaliturri F.The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL)[J].Best Pract Res Clin Haematol, 2012, 25:185-190.
[11] Wang M, Fayad L, Wagner-Bartak N, et al.Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma:aphase1/2clinical trial[J].Lancet Oncol, 2012, 13:716-723.
[12] Zaja F, De Luca S, Vitolo U, et al.Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma:clinical results and effects on microenvironment and neo-angiogenic biomarkers[J].Haematologica, 2012, 97:416-422.
[13] Morrison VA, Jung SH, Johnson J, et al.Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma:final results of a phase II trial (CALGB 50501)[J].Leuk Lymphoma, 2015, 56:958-964.
[14] Ruan J, Martin P, Shah B, et al.Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma[J].N Engl J Med, 2015, 373:1835-1844.
[15] 陈永春, 范磊, 徐卫, 等.套细胞淋巴瘤诊断和治疗进展[J].临床血液学杂志, 2016, 29 (5):424-427.
[16] Rummel MJ, Niederle N, Maschmeyer G, et al.Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas:an open label, multicentre, randomised, phase 3non-inferiority trial[J].Lancet, 2013, 381:1203-1210.
[17] Abrahamsson A, Albertsson-Lindblad A, Brown PN, et al.Real world data on primary treatment for mantle cell lymphoma:a Nordic Lymphoma Group observational study[J].Blood, 2014, 124:1288-1295.
[18] Alexandra AL, Arne K, Anna L, et al.Lenalidomidebendamustine-rituximab in patients older than 65years with untreated mantle cell lymphoma[J].Blood, 2016, 128:1814-1820.
[19] Flinn IW, Mainwaring M, Peacock N, et al.Rituximab, lenalidomide, and bortezomib in the first-line or second-line treatment of patients with mantle cell lymphoma a phase I/II trial[C].ASH Annual Meeting Abstracts, 2012, 120:2748.
-
计量
- 文章访问数: 33
- PDF下载数: 17
- 施引文献: 0
下载: